Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Statement of Cash Flows [Abstract]
Net earnings	$ 2,230	$ 2,745
Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation	367	367
Amortization of intangible assets	3,722	3,838
Deferred income taxes	(300)	(405)
Change in fair value of contingent consideration liabilities	4,313	2,136
Payments of contingent consideration liabilities	(1,408)	(876)
Stock-based compensation	589	566
Acquired IPR&D and milestones	1,071	1,101
Non-cash litigation reserve adjustments, net of cash payments	(750)	27
Other, net	96	(53)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(1,496)	(524)
Inventories	(211)	(127)
Prepaid expenses and other assets	(257)	309
Accounts payable and other liabilities	(181)	(1,337)
Income tax assets and liabilities, net	(997)	(1,456)
Cash flows from operating activities	6,788	6,311
Cash flows from investing activities
Payments to Acquire Businesses, Net of Cash Acquired	(204)	(9,199)
Other acquisitions and investments	(1,274)	(1,033)
Acquisitions of property and equipment	(504)	(434)
Purchases of investment securities	(22)	(22)
Sales and maturities of investment securities	39	9
Other, net	49	(11)
Cash flows from investing activities	(1,916)	(10,690)
Cash flows from financing activities
Net change in commercial paper borrowings with original maturities of three months or less	1,549	0
Proceeds from issuance of other short-term borrowings	4,007	5,008
Repayments of other short-term borrowings	0	(5,008)
Proceeds from issuance of long-term debt	3,994	14,963
Repayments of long-term debt and finance lease obligations	(6,780)	(3,448)
Debt issuance costs	(23)	(99)
Dividends paid	(5,835)	(5,522)
Purchases of treasury stock	(973)	(1,333)
Proceeds from the exercise of stock options	61	137
Other, net	32	24
Cash flows from financing activities	(3,968)	4,722
Effect of exchange rate changes on cash and equivalents	39	(27)
Net change in cash and equivalents	943	316
Cash and equivalents, beginning of period	5,524	12,814
Cash and equivalents, end of period	$ 6,467	$ 13,130

AbbVie Inc. 10-Q